Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004

Ann Rheum Dis. 2004 Nov;63 Suppl 2(Suppl 2):ii2-ii12. doi: 10.1136/ard.2004.029272.

Authors

D E Furst¹, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, P J Mease

Affiliation

¹ University of California, Rheumatology Division, 1000 Veteran Avenue Rehabilitation Centre, Room 32-59, Los Angeles, CA 90024, USA. defurst@mednet.ucla.edu.

No abstract available

Publication types

Consensus Development Conference
Review

MeSH terms

Antirheumatic Agents / adverse effects
Antirheumatic Agents / therapeutic use*
Humans
Immunologic Factors / adverse effects
Immunologic Factors / therapeutic use*
Interleukin 1 Receptor Antagonist Protein
Receptors, Interleukin-1 / antagonists & inhibitors
Rheumatic Diseases / drug therapy*
Sialoglycoproteins / adverse effects
Sialoglycoproteins / therapeutic use*
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antirheumatic Agents
IL1RN protein, human
Immunologic Factors
Interleukin 1 Receptor Antagonist Protein
Receptors, Interleukin-1
Sialoglycoproteins
Tumor Necrosis Factor-alpha